Full metadata record

DC Field Value Language
dc.contributor.authorChang, Jeong-Soo-
dc.contributor.authorEl-Gamal, Mohammed I.-
dc.contributor.authorLee, Woong San-
dc.contributor.authorAnbar, Hanan S.-
dc.contributor.authorChung, Hye Jin-
dc.contributor.authorKim, Hyun-Il-
dc.contributor.authorCho, Young-Jin-
dc.contributor.authorLee, Bong Sang-
dc.contributor.authorLee, Sun Ahe-
dc.contributor.authorMoon, Ji Yun-
dc.contributor.authorLee, Dong Jin-
dc.contributor.authorJeon, Hong-Ryeol-
dc.contributor.authorLee, Jaehwi-
dc.contributor.authorChoi, Young Wook-
dc.contributor.authorOh, Chang-Hyun-
dc.date.accessioned2024-01-20T16:30:47Z-
dc.date.available2024-01-20T16:30:47Z-
dc.date.created2022-01-10-
dc.date.issued2011-09-
dc.identifier.issn0223-5234-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/130006-
dc.description.abstractSynthesis of new ester prodrugs of olmesartan is described. Their in vitro stabilities in simulated gastric juice, rat plasma, and rat liver microsomes were tested. And the pharmacokinetic parameters for olmesartan after their oral administration were also estimated and compared with those in case of olmesartan medoxomil. Compounds 13 and 14 demonstrated high stability in simulated gastric juice and were rapidly metabolized to olmesartan in rat liver microsomes and rat plasma in vitro. In addition, C-max and AUC(last) parameters were significantly increased in case of compounds 13 and 14 compared with olmesartan medoxomil. These results indicate that compounds 13 and 14 with cyclohexylcarboxyethyl and adamantylcarboxymethyl promoieties, respectively, are promising prodrugs of olmesartan with markedly increased oral bioavailability. (C) 2011 Elsevier Masson SAS. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER-
dc.subjectANGIOTENSIN-CONVERTING ENZYME-
dc.subjectII RECEPTOR ANTAGONISTS-
dc.subjectBLOCKER-
dc.subjectMEDOXOMIL-
dc.subjectRENIN-
dc.titleDesign, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan-
dc.typeArticle-
dc.identifier.doi10.1016/j.ejmech.2011.05.019-
dc.description.journalClass1-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.46, no.9, pp.3564 - 3569-
dc.citation.titleEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY-
dc.citation.volume46-
dc.citation.number9-
dc.citation.startPage3564-
dc.citation.endPage3569-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000295237400003-
dc.identifier.scopusid2-s2.0-80052942627-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusANGIOTENSIN-CONVERTING ENZYME-
dc.subject.keywordPlusII RECEPTOR ANTAGONISTS-
dc.subject.keywordPlusBLOCKER-
dc.subject.keywordPlusMEDOXOMIL-
dc.subject.keywordPlusRENIN-
dc.subject.keywordAuthorAntihypertensive-
dc.subject.keywordAuthorOlmesartan-
dc.subject.keywordAuthorOlmesartan medoxomil-
dc.subject.keywordAuthorProdrug-
dc.subject.keywordAuthorEster-
dc.subject.keywordAuthorPharmacokinetics-
Appears in Collections:
KIST Article > 2011
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE